

Date: 31st May, 2022

BSE Ltd.
Corporate Service Department
1st Floor, P.J. Towers,
Dalal Street,
Mumbai 400 001

The National Stock Exchange of India Ltd.
Exchange Plaza, 3rd Floor,
Plot No. C/1, 'G' Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

Scrip ID: KRSNAA
Scrip Code: 543328

Symbol: KRSNAA
Series: EQ

Dear Sir/Madam,

Subject: FY21-22 Earnings Presentation

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith an Earnings Presentation on Audited Financial Results of the Company for quarter and year ended on 31st March, 2022.

Request you to take the same on your records.


Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Nikhil Deshpande
Company Secretary





Krsnaa
DIAGNOSTICS

LET'S DO GOOD...



One of INDIA'S LARGEST
Differentiated Diagnostic
Service Provider

FY2022 & Q4 Investors Presentation



FY2022 and Q4 Performance

Strong Performance Across All Key Performance Indicators



47%
Revenue CAGR
5Y (FY17-22)

101%
PAT** CAGR
5Y (FY17-22)

46
Receivable Days
31st March, 2022

2,071
Centres

23+ Mn
Patients Served
Last 5 Years

14+ States

70+ Districts Locations

17+ Mn No. of Tests annually

1+ Mn CT/MRI scans per annum

3+ Mn X-Rays per annum

12+ Mn Pathology tests per annum


Notes:
* EBITDA is excluding CSR and ESOP expenses
** PAT without exceptional Items

FY2022: Strong Revenue and Net Profit Growth


Core Business Continues to Deliver Stellar Revenue Growth of 70% Y-o-Y
Strong EBITDA of Rs. 133 Cr with margins of 29% and Net Profit of Rs. 68 Cr, up by 117% Y-o-Y

Rs. Million


Total Revenue




Core Business Revenue




Covid-19 Revenue




EBITDA*



Profit After Tax**



Revenue Mix



Notes:

* EBITDA is excluding CSR and ESOP expenses


** PAT without exceptional Items

Q4 FY2022: Strong Net Profit Growth


In Q4 FY22, Revenue up by 13% and Net Profit up by 21%. Performance driven by Core Business
EBITDA was impacted due to investment in operationalizing new centres and increase in employee cost

Rs. Million


Total Revenue




Core Business Revenue




Covid-19 Revenue




EBITDA*



Profit After Tax**



Revenue Mix



Notes:


* EBITDA is excluding CSR and ESOP expenses

** PAT without exceptional Items

Core Business Volumes Continues to Grow

Tests In Million

Total Number of Tests







- Strong tests volume growth visible in all modalities
- Higher awareness and visibility of Krsnaa diagnostics centres
- High quality services at disruptive prices driving patient and tests count
- Addition of 20 Radiology, 103 Tele-reporting and 118 Pathology centres during the year

Radiology Tests

Tele-Reporting Tests

Pathology Tests

Covid-19 Tests




Operational Performance Trend

Strong Increase in Patient Count and Average Revenue Per Patient up from Pre-Covid-19 Levels


Number of Patients* (in Mn)

58% Y-o-Y




Tele-Reporting Patients (in Mn)


40% Y-o-Y



Average Revenue Per Patient** (in Rs)



Average Revenue Per Patient (in Rs): Tele-Reporting



* Number of Patients (Radiology and Pathology) excluding Tele-Reporting


** ARPP (Radiology and Pathology) excluding Tele-Reporting




Annual Performance Trends

Revenue and Profit After Tax Growth Trend

Revenue (in Mn)



Profit After Tax* (in Mn)




*PAT without exceptional Items
Last 5 Years CAGR is for the period FY2017-22

Well Diversified Business Mix


Radiology and Pathology Revenue grew by 5.5 times and 8.2 times respectively in Last 5 Years

Remains one of the Fastest Growing Diagnostics Service Provider

Radiology Revenue*



Pathology Revenue excluding Covid-19




Rs. Million


- Radiology Revenue is including tele-reporting
- Last 5 Years CAGR is for the period FY2017-22

Strong Cash Collection and Cash Flow Conversion

Receivables Days



EBITDA to Cash Flow Conversion*



- Krsnaa has built a strong cash flow generating business model backed by strong cash flow conversion cycle and efficient working capital management
- Total net cash generated from operations after tax of Rs. 128 Crores in FY22
- Receivables days continues to decline to 46 days at the end of FY22, reflects timely collection of dues from national health agencies
- Krsnaa maintains strong EBITDA to Cash Flow conversion ratio, which allows company to fund its growth plans through internal accruals

* EBITDA to Cash Flow Conversion calculated as Cash Flow from Operating Activities Before Tax/ EBITDA

Well Capitalized Balance Sheet to Fund the Growth

(Rs. Million)	FY18	FY19	FY20	FY21	FY22
Long Term Debt	556	937	1,400	1,680	331
Short Term Debt	452	772	1,112	638	79
Total Debt (A-B)	1,008	1,709	2,512	2,318	410
Cash & Cash Equivalents	219	1,281	1,379	1,624	3,480
Net Debt / (Net Cash) (A-B)	789	428	1,133	694	(3,070)
Total Equity	806	1,890	2,014	2,319	6,868
Cash Flow From Operating Activities Before Tax	351	681	516	1,102	1,351

- **Krsnaa Diagnostics strengthens its balance sheet with strong cash flow generation**
- Repaid Total Principal Debt of Rs. 1,908 Mn in FY22 by utilizing Rs. 479 Mn funded from internal accruals and Rs. 1,429 Million out of IPO proceeds
- Capex of Rs. 1,311 Mn was incurred during the period, out of which Rs. 721 Mn was funded from internal accrual and Rs. 590 Mn was funded from IPO proceeds. This was primarily incurred towards setting up new diagnostics centre

Annual Financial Performance – Delivering Consistent Growth

(Rs. Million)	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	Y-o-Y Growth FY21-22	CAGR Growth FY17-22
Core Business	668	1,081	2,098	2,584	2,492	4,236	70.0%	45%
Covid-19 Business	-	-	-	-	1,473	319	(78.4)%	-
Revenue from Operations	668	1,081	2,098	2,584	3,965	4,555	14.9%	47%
Other Income	38	14	23	103	122	149	21.9%	31%
Total Income	706	1,095	2,121	2,687	4,087	4,704	15.1%	46%
EBITDA¹	145	292	598	643	953	1,333	39.9%	56%
Margin %	21.7%	27.0%	28.5%	24.9%	24.0%	29.3%	523bps	
EBIT²	85	131	365	422	686	1,050	53.0%	65%
Margin %	12.7%	12.1%	17.4%	16.3%	17.3%	23.1%	575bps	
Profit After Tax³	21	49	125	125	315	684	116.9%	101%
Margin %	3.1%	4.5%	5.9%	4.8%	8.0%	15.0%	706bps	
Reported Diluted EPS	(7.6)	(2.20)	12.95	9.70	12.25	22.88	86.7%	-

Notes:

1. EBITDA is excluding CSR and ESOP expense
2. EBIT including Other Income
3. Profit After Tax is calculated without exceptional Items

Quarterly Financial Performance

(Rs. Million)	Q4FY22	Q4FY21	Y-o-Y Growth	Q3FY22	Q-o-Q Growth
Core Business	1,062	830	28.1%	1,052	1.0%
Covid-19 Business	20	129	(84.5)%	13	-
Revenue from Operations	1,082	959	12.9%	1,065	1.7%
Other Income	41	29	43.3%	43	(5.4)%
Total Income	1,123	988	13.7%	1,108	1.4%
EBITDA¹	284	338	(15.9)%	304	(6.7)%
Margin %	26.2%	35.2%		28.6%	
EBIT²	217	263	(17.7)%	237	(8.6)%
Margin %	20.0%	27.5%		22.3%	
Profit After Tax³	179	148	21.4%	163	10.1%
Margin %	16.6%	15.4%		15.3%	
Reported Diluted EPS	5.40	(9.53)	-	5.64	(4.3)%

Notes:

1. EBITDA is excluding CSR and ESOP expense
2. EBIT including Other Income
3. Profit After Tax is calculated without exceptional Items

Balance Sheet


Assets (In Million)	FY21	FY22
Non-Current Assets	3,563.91	5,420.06
Property, plant and equipment	3,072.80	3,833.79
Capital work-in-progress	37.18	282.57
Intangible assets	12.28	23.15
Intangible asset under development	-	-
Financial assets		
Investments	2.90	2.91
Loans	-	-
Other financial assets	159.51	1,155.15
Deferred tax asset (net)	0.00	7.88
Other non-current assets	279.24	114.61
Current Assets	2,528.86	3,341.47
Inventories	72.10	91.70
Financial assets		
Trade receivables	752.89	578.73
Cash and cash equivalents	246.75	884.53
Bank balances other than cash and cash equivalent	1,282.37	1,534.28
Other financial assets	90.08	118.56
Other current assets	84.67	133.67
Total Assets	6,092.77	8,761.53

Equity and Liabilities (In Million)	FY21	FY22
Total Equity	2,318.65	6,844.09
Equity share capital	64.95	156.99
Instruments entirely equity in nature	2,423.90	0.00
Other equity	(170.20)	6,687.10
Non-Current Liabilities	1,888.60	429.48
Borrowings	1,529.26	196.22
Lease Liabilities	150.28	134.52
Liability on compulsory convertible preference shares	-	-
Other financial liabilities	63.89	16.38
Employee benefit obligations	5.19	3.16
Other non-current liabilities	33.03	1.25
Deferred tax liabilities	106.95	77.95
Current Liabilities	1,885.52	1,487.96
Borrowings	620.76	60.08
Lease Liabilities	17.49	19.10
Trade payables		
i) total outstanding dues of MSME	5.37	3.27
ii) total outstanding dues of creditors other than MSME	827.66	769.73
Other financial liabilities	374.73	512.57
Employee benefit obligations	9.28	19.81
Short term provisions	-	-
Other current liabilities	30.23	103.40
Total Equity and Liabilities	6,092.77	8,761.53

Business Overview



Track Record of Successful Fast-Pace Expansion





Radiology Centres

107 Centres
CT Scans and MRI



1,381
Tele-Reporting Centres



1,488
Radiology Centres



Pathology Labs


49
Processing Labs




534
Collection Centres




583
Pathology Centres



Only Company with Pan India Presence in Both Radiology and Pathology



FY2022 Regional Revenue Contribution Mix




High Headroom to Grow

- Highest penetration across districts with presence in 70+ out of 700+ districts; still large underpenetrated market
- Government continuous focus on improving healthcare in India and looking to partner under PPP model
- Krsnaa is already present in most of the tier I, II, III and rural areas. Krsnaa plans to leverage its extensive presence for growth

*Under Implementation
** The USG, Dexa, Mammography and TMT Centres are not marked in this map.

Tapping Wide Spectrum of Market Unaddressed by Peers

Krsnaa Remains Fastest Growing Diagnostic Service Provider and Continues to Tap Wide Spectrum of Underpenetrated Market
Krsnaa is the Only Listed Company with Well Diversified Business Mix of Radiology and Pathology



Minimal Competition from Regional Chains due to:

- Krsnaa expertise and scale of business
- Access to high-cost radiology machines at relatively lower prices

Entry Limitations:

- High capex, low opex model is tough to enter
- Disruptive pricing model makes it tough for competition to compete
- Larger chains focused on pathology tests

High Quality Diagnostic Services at Disruptive Prices

Krsnaa Offers Tests at 45-60% Lower than Market Rates

Segment	Test	Player 1	Player 2	Player 3	Krsnaa	% from min price
RDL	CT Brain	4,500	4,500	3,500	2,000	(43%)
RDL	MRI Brain	8,000	8,250	7,000	3,500	(50%)
PTH	CBC	250	250	200	146	(27%)
PTH	Blood Sugar	85	80	70	26	(63%)
PTH	Thyroid	500	550	550	216	(57%)
PTH	Vitamin D	1,500	1,250	1,450	595	(52%)
PTH	Vitamin B12	1,000	1,100	1,300	243	(76%)
PTH	HbA1C	550	440	400	141	(65%)

Krsnaa Diagnostics offers high quality diagnostics services at disruptive prices

Well placed to withstand any industry price caps as well pricing pressure on tests

Cost Disruption...



Low fixed cost of operations



Digital transmission of scans




Limited promotional expense




Efficient procurement of scans

Leading to a Virtuous Cycle..

Ability to offer deep discounts on prices thus ensuring higher footfalls and making Krsnaa the preferred partner for governments and hospitals



Krsnaa Diagnostics hub and spoke model radiology facility in Pune is fully capable to process large volumes



- **Scalable** business model and enables wider penetration into tier II and tier III cities
- Analog images gets **converted into digital format** and sent to hub for examining and preparing report. **Addresses the shortage of full-time doctors** and staff in the diagnostics industry
- **Experienced** team of radiologists and lab technicians
- **Stringent quality control checks** to ensure highest reporting standards coupled and accurate diagnosis
- Krsnaa Diagnostics organizes **regular training session** to enhance skills of the workforce and keep them apprised of the latest technological advancement in the field of diagnostics
- **Sufficient capacity** to process large volumes in the coming years

4,578 Sq.ft. Well designed facility at Pune	190+ Team of in-house tele-reporting radiologists from India and abroad	24x7 Uninterrupted connectivity between diagnostic centres and the hub
---	---	--

Test	Monthly Capacity	FY22 Annual Volumes	Headroom
CT Scans	1,45,000	7,27,466	2.4x
MRIs	40,000	2,31,698	2.1x
Tele Reporting	2,000,000	34,21,875	7.0x

Sustainable business model backed by underlying competitive advantages and well positioned to drive growth

1

Revenue Visibility

- **Long-term of contracts (between 5-10 years)** with inbuilt price escalation mechanism ensures higher and consistent visibility of revenues
- Government focus on investing in healthcare at underpenetrated rural and municipal corporations will provide an impetus to PPP model

2

Captive Customer Base

- Large addressable customer base from Day 1 of operations, as majority of the population is treated at government hospitals
- Customer base is **driven by both patient's visiting government hospitals and direct walk-ins driven** by relatively cheaper rates with best-in class infrastructure and timely reporting

3

Cost Efficiencies

- **Zero doctor referrals fees** for patient acquisition and limited expenses incurred in marketing and promotion
- **Zero rentals to government hospitals** for providing the space and availability of subsidized utility and electricity rates
- Due to large procurement, equipment is purchased at lower cost and CMC contracts are availed at discounts

4

Operational Synergies

- **Unique tele-reporting hub in Pune** ensures quick and efficient services for both new and existing facilities
- Centralized operations ensure most proficient doctor and radiologist are engaged over long term with an efficient payout structure for both

5

Higher Tender Renewal Probability

- Existing investment on equipment and infrastructure, large scale of operations and cost competitiveness have resulted in **strong bid-win rate of 78%** in the past and trend is expected to continue
- Ability to quote attractive pricing at the time of renewal and strong track record of successfully renewing the contract



Strategic Pillars of Growth

Target is to achieve 2x growth in Revenues and 3x growth in Profits by end of FY2024



Tap the growing and underpenetrated diagnostic market by participating in new PPP tender



Focus on timely and successful implementation of new projects



Enhanced centre profitability with the maturing centres



Expand Pathology business by capitalizing on the extensive infrastructure of existing Pathology Diagnostics centres, adding more collection centres and reaching to end consumers



Digital marketing and creating awareness about Krsnaa's disruptive price offerings

**Krsnaa has recently won 3 PPP contracts to deploy 8 CT, 1 MRI with duration of 10 years
Establish 24 Pathology and 190 Collection centres with duration of 5 years**

Uttar Pradesh Radiology Contract

- UP Government awarded contract in February 2022. National Health Mission backed contract
- Duration 10 Years
- Deploy 8 CT scanners in districts hospitals

Chandigarh Radiology Contract

- Chandigarh health department awarded contract in February 2022
- Duration 10 Years
- Deploy 1 MRI scanners at Govt. Multi Specialty Hospital, Chandigarh

Himachal Pradesh Pathology Contract

- Himachal Pradesh department of health and family awarded contract in February 2022
- Duration 5 Years
- Establish 24 Labs and 190 collection centres with Hub and Spoke model

Projects Mentioned in RHP: Implementation on Track

Radiology Centres Growth

State	Total Centres	Operational Till March 22	To be Operationalized in Q1 FY23	Construction Completed	Construction WIP
Punjab	25	9	7	8	1
MCGM Mumbai	3	1	1	-	1
Himachal Pradesh	2	2	-	-	-
Karnataka	2	1	-	-	1
Somaiya Hospital Mumbai	1	-	1	-	-
Total Radiology	33	13	9	8	3

Pathology Centres Growth

State	Total Centres	Operational Till March 22	To be Operationalized in Q1 FY23	Construction Completed	Construction WIP
Punjab Labs	30	7	11	8	4
Punjab Collection Centres	95	77	2	-	16
Total Pathology	125	84	13	8	20

Total Capital Expenditure incurred of Rs. 59 Crore from IPO Proceeds for setting up new centres

Projects Mentioned in RHP: Implementation on Track

High quality infrastructure and services at disruptive prices creates market awareness and drives direct walk-ins

Branding at Centres



Branding at Centres



World Class Infrastructure



Strong Support from All Stakeholders




Krsnaa Younger Portfolio Continues to Mature with Promising Future



64% Gross Block* **33%** ROCE

Matured

- Expand B2C share of Business
- Focus is on increasing patient touch points, awareness and visibility
- Standardize patient test reports and improve patient experience at the centres
- Focus on the training of employees to enhance overall productivity and operational efficiencies



20% Gross Block* **11%** ROCE

Semi-Matured

- Increase awareness and visibility through digital marketing
- Add more collection centres, tieup with nursing homes, hospitals to drive test volumes
- Ensure shorter reports turnaround time and maintain high accuracy
- One roof solution for Radiology and Pathology at all centres
- Directory of test menu sanitization





16% Gross Block* **-10%** ROCE

Newly Launched

Notes:

1. * Gross Block % is calculated as on the year ended 31st March, 2022
2. Maturity is on the basis of the project start date
3. Return on Capital Employed calculated as (EBIT including Other Income / Gross Block)

Retail Market Expansion Strategy




Capitalizing on the extensive infrastructure of Pathology Diagnostics and extending it to end consumers

583
Pathology Centres

49
Processing Labs

534
Collection Centres

- Expanding B2C pathology diagnostic service offerings at disruptive prices in 5 states
- Phase I – Maharashtra and Punjab and Himachal Pradesh
- Phase II – Rajasthan and West Bengal
- Plan is to open 1,000 collection centres in these states
- Capitalizing on the existing infrastructure of Pathology centres
- Further expand B2C in other remaining states and adding more collection centres to penetrate deeper into key markets
- B2C to enhance overall operational efficiencies



Enhancing Visibility, Awareness and Convenience Through Digital Initiatives

Re-Launch Mobile Application

- Digitalize reports and provide Smart Health Reports with next steps and recommendations
- Real time availability of reports
- One roof for Radiology and Pathology
- Conveniently book appointment for Radiology tests
- Book appointment for home collection

Patient Testimonials

- Encourage patients to provide feedback and write testimonials about the experience with Krsnaa
- Post testimonials on social media platforms to create awareness and visibility
- Collect feedback on scope of improvement areas



Social Media Engagement

- Organize social media engagement campaigns on health awareness & free cancer camps
- Participate in health and talk shows
- Increasing touch points through regular social media engagement and sharing of information

Wellness and Illness Packages

- Increase awareness about preventive health check ups at disruptive prices
- Customize test health packages according to the region and states
- Launch home collection and homecare services

IN-SHOP BRANDING

We are here to provide a complete range of tests for you and your family.



Krsnaa
DIAGNOSTICS®
LET'S DO GOOD.™

#Let'sdodgood.™ www.krsnaadiagnostics.com

Any medical emergency in your family – We provide 24*7 diagnostic services at all our centers.



Krsnaa
DIAGNOSTICS®
LET'S DO GOOD.™

#Let'sdodgood.™ www.krsnaadiagnostics.com

PROMOTIONAL BRANDING

LET'S DO GOOD

Become a Krsnaa Business Associate (KBA)
Let's join hands together with best-in-class integrated diagnostics company for well being of India

13+	14	1800+	59	500+
Million lives served	States	Locations	Pathology Labs	Collection Centers

Why choose Krsnaa / KBA:

- 24hrs processing lab
- Lesser Turnaround Time
- Affordable Price
- Pre-paid model
- User friendly software
- In-house logistics team
- Marketing Support (Print/Digital)
- Training Support
- Brand Value
- Radiology Support

Helpline: 020-6814 6814, 4695 4695 | WhatsApp: 96233 96233

Krsnaa Diagnostics Ltd

Our Services

- Pathology
- CT Scan
- MRI Scan
- Digital X-Ray

Our Presence Across India



- India's Largest Healthcare PPP Service Provider
- ISO 9001:2015 Company
- NABL Accredited Centers
- 10- NABL Accredited Labs
- 9-ICMR Approved Labs
- Affordable Prices
- Home Blood Collection
- 24x7 Emergency Service
- 14 States, 2000+ Locations
- 10,000,000 Radiology & Pathology studies per year

Helpline: 020-6814 6814, 4695 4695 | WhatsApp: 96233 96233

For more details visit: www.krsnaadiagnostics.com

Our Expert medical professionals provide accurate diagnosis for your right treatment.



Krsnaa
DIAGNOSTICS®
LET'S DO GOOD.™

#Let'sdodgood.™ www.krsnaadiagnostics.com

Order of Draw

Cap Colour	Inversions	Common Tests
Sterile samples (eg. Blood Culture Bottle)		
Light Blue - Sodium Citrate	4	PT / APTT and All Thrombin II, Prothrombin II, Prothrombin I
Gold - Serum Clot activator with Gel	5	All Serum Studies
Red - Plain Serum Clot activator	3	All Serum Studies (Chemistry)
Green - Sodium / Lithium Heparin Tube	6	All Plasma Studies (Chemistry)
Lavender - EDTA Tube	8	CBC / HbA1c / GSPD / MP / Hematology etc.
Grey - Fluoride Tube	8	Glucose, Glucose Tolerance Test, Lactic Acid etc.
Black - ESR™ Tube	4	ESR

Preferable Sites for Phlebotomy



- Median Cubital Vein
- Cephalic Vein
- Basile Vein

Blood Collection - Best Practices

- Cleaning to be done in circular motion from center to periphery.
- Allow the Alcohol / Spirit to air dry for atleast 30 - 60 sec. before needle insertion.
- Do not touch the site after cleansing.
- tourniquet should not be kept more than 1 min.
- Release / Loosen the tourniquet before withdrawing the needle from the vein.
- Avoid collection from Arm side of - Mastectomy, Edema, Hematoma, Burns, Scars, Tattoos, IV cannula.

Put the garbage in a suitable colored box

- Poor and Physical Wastes (Disposable, Chemicals, Pathology, Microbial and other Laboratory Waste etc.)
- Sharps objects like Needle, Scalpel etc.
- Contaminated Plastic etc.
- Sharps objects like Needle and Scalpel (Glass, Plastic, Metal, etc.)
- Sharps objects like Needle and Scalpel (Glass, Plastic, Metal, etc.)
- Sharps objects like Needle and Scalpel (Glass, Plastic, Metal, etc.)

How to handrub? (with hand sanitizer)



How to handwash? (with soap and water)



Krsnaa Diagnostics Ltd. (Formerly known as Krsnaa Diagnostics Pvt. Ltd.)
24x7 Helpline No.: 92272 79292 | 020-6814 6814 | 020 4695 4695

Experienced Leadership Team



Rajendra Mutha
Executive Chairman

- 10+ years of experience in the field of pharmacy and diagnostics
- Registered pharmacist certified by the Maharashtra State Pharmacy Council



Pallavi Bhatevara,
Managing Director

- 8 years of experience in the field of diagnostic services
- Responsible for expansion and growth
- Involved in the tendering process and implementation and execution of projects



Yash Mutha
Whole Time Director

- 12+ years of experience in the field of audit and risk management
- CA, CISA, CFE
- Previously associated with KPMG, Deloitte, Credit Suisse



Dr. Ravinder Sethi
Chief Operating Officer

- 24+ years of experience in the field of business management and transforming organizations
- Doctorate, Business Administration and Management from Azteca University, Mexico
- PGDBM in Sales & Management



Dr. Manish Karekar
Chief Operating Officer - Pathology

- 14+ years of experience in the field of Pathology science
- MBBS and MD from Mumbai University as well as Six Sigma Black belt from ISI, Pune
- Focused on innovation and sustenance of standardized processes across all laboratory



Dr. Abhiji Patil,
Vice President - Radiology

- 13+ years of experience and has done his MD-Radiodiagnosis
- An academic experience as a Professor and Associate Professor in renowned institute
- Experience in sectional imaging including CT, MRI, PET CT and Fusion PET MRI.



Pawan Daga
Chief Financial Officer

- 10+ years of experience in mergers and acquisitions, treasury and funding, investor relations, cost management, financial operations, legal, taxation, financial accounting, and reporting
- Chartered Accountant and Masters of Commerce from Pune University



Nikhil Deshpande
Company Secretary

- 10+ years of experience of working in the Company Secretarial field skilled in IPO, SEBI Regulations, Investor Relations, Corporate Restructuring, ESOPs, Corporate Governance & FEMA Compliance
- Qualified Company Secretary and Law Graduate from Pune University

Board of Directors – Diversified Experience and Background



Chetan Desai
Independent Director

- Practicing Chartered Accountant with a wide-spread experience of 47 years
- He was the Managing Partner of M/s. Haribhakti & Co. LLP, Chartered Accountants till March 2018
- As an Independent Director, he serves as the Chairman of the Audit Committee and also as a member of the Nomination and Remuneration Committee of the Board.



Chhaya Palrecha
Independent Director

- Chartered Accountant with 24 years of experience
- She has led finance and accounts functions of corporate entities for the last 22 years in varied manufacturing and service industries.
- As an Independent Director, she serves as a member of the Audit Committee, Stakeholders' Relationship Committee and Nomination and Remuneration Committee of the Board



Rajiva Ranjan Verma
Independent Director

- Superannuated as Director General of Police, Railway Protection Force, in 2016, after 38 years of career
- He held key assignments of Director General, Bureau of Police Research & Development, National Crime Record Bureau and Civil Defense
- As an Independent Director, he serves as the Chairman of the Risk Management Committee and also as a member of the Audit Committee as well as Corporate Social Responsibility Committee



Adesh Kumar Gupta
Independent Director

- Qualified Chartered Accountant, Company Secretary and AMP from Harvard is a professional with rich experience of over more than 40 years in Corporate Strategy, M&A, Business restructuring, Fund raising, Taxation etc.
- Career of over 3 decades in Aditya Birla Group, held various senior positions including board positions in various companies of the group including Indian Rayon, Birla Global Finance, Aditya Birla Nuvo Limited and Grasim Industries Limited




Prem Pradeep
Nominee Director

- B.Tech in Mechanical Engineering from IIT Delhi and a PGDM from IIM Calcutta
- Over 40 years of experience. Held senior management positions with Bharti Infratel (CEO), Bharti Airtel (CEO), PepsiCo India (VP), RPG group (CEO e-business).
- Currently, he is working as an operating partner with Phi Capital
- As a Nominee Director, he serves as a member of the Audit, Nomination and Remuneration Committee and Corporate Social Responsibility Committee

Note:

1. Leadership Team members, Rajendra Mutha is the Executive Director and Chairman, Pallavi Bhatevara is the Executive Director and Managing Director, Yash Mutha is the Executive Director.
2. Mr. Adesh Kumar Gupta has been appointed as an Independent Director w.e.f 28th May, 2022

One of the **Fastest Growing Diagnostics Service Provider** in the country



Total Centre count increased at a **CAGR of 32%** from 682 in FY18 to 2050+ in FY21

Extensive Geographic Footprint



Centres across India with **presence in 14 States**. Diagnostic equipment is state-of-the-art and procured from leading OEMs

Strong Brand Equity



Well positioned to partner with the Government's initiative to provide **equitable, affordable and quality health care services**

Scalable and Agile Business Model



PPP is an asset light model which ensures robust revenue and **long-term contract provides revenue visibility**

Disruptive Pricing




Ability to **maintain cost competitiveness underpinned by leading volumes**, higher economies of scale and optimize cost structure

Stakeholder Value Creation



Defined strategy to deliver sustainable long-term growth

Shareholding Pattern as on 31st March, 2022



Top Institutional Shareholders – 31 st March, 2022	% Holding
Aditya Birla Sun Life	3.7%
Tata AIA Life Insurance	3.7%
Tata Mutual Fund	3.2%
ICICI Prudential Pharma Healthcare	3.1%
HDFC Life Insurance Company	2.8%
Invesco India Growth Opportunities	2.4%
HSBC Global Investments	2.1%

47%

Revenue CAGR
5Y (FY17-22)

101%

PAT CAGR
5Y (FY17-22)

45%

Radiology Revenue
CAGR 5Y (FY17-22)

52%

Pathology Revenue
CAGR 5Y (FY17-22)

31%

Total Centre Count
CAGR 5Y (FY17-22)

46

Receivables Days
FY2022

**Target is to achieve 2x growth in Revenues and
3x growth in Profits by end of FY2024**

Key Valuation Metrics	27-May-22
NSE Ticker	KRSNAA
BSE Ticker	543328
Share Price (in Rs)	523
Number. of Shares (in Cr)	3.14
Equity Value (Rs. Cr)	1,642
Gross Borrowings (Rs. Cr) – 31 March, 22	41.0
Cash and Cash Equivalents (Rs. Cr) – 31 March, 22	-348.0
Net Debt / (Net Cash) (Rs. Cr)	-307.0
Enterprise Value (Rs. Cr)	1,334.6
Adjusted Profit After Tax (Rs. Cr)	68.4
EBITDA in (Rs. Cr)	133.3
Adjusted P / E	24.0x
EV / EBITDA	10.0x

This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact:

Krsnaa Diagnostics

Nikhil Deshpande, Company Secretary
cs@krsnadiagnostics.com

Contact: +91 20 4695 4695

Churchgate Partners

Ravi Gothwal / Vikas Luhach
krsnaa@churchgatepartners.com

Contact: +91 22 6169 5988